GSKs Gepotidacin Could Become First Novel Antibiotic For uUTIs In 20 Years
Following Pivotal Success
The UK major’s first-in-class asset has matched standard-of-care in two Phase III urinary tract infection trials, setting it up to become the first novel antibiotic for the condition in 20 years with a clear niche in the second-line setting.
You may also be interested in...
GSK Boosts Its Infectious Disease Portfolio With Brexafemme License
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
AbbVies Rinvoq Succeeds Against The Odds In Phase II Lupus Trial
Despite a troubled history of JAK inhibitors in lupus trials, AbbVie’s Rinvoq has hit the mark in a mid-stage study of the condition, shifting focus to a pivotal program that could expand the blockbuster drug’s reach.
Addressing The Rare Disease Challenge Via Patient Engagement
Following the FDA’s release of draft guidance to enhance patient voice, In Vivo spoke with Ipsen’s rare disease regulation expert on creating a more patient-centric R&D and approval pathway, from modified endpoints to trial decentralization and beyond.